-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network, June 8 News On June 7, Qilu Pharmaceutical declared the imitation listing of four types of emtricitabine propofol tenofovir tablets (I) and emtricitabine propofol tenofovir tablets (II).
Application, at present, only original research drugs in China have been approved for import in 2018, and no domestic generic drugs have been approved for the time being
.
Application, at present, only original research drugs in China have been approved for import in 2018, and no domestic generic drugs have been approved for the time being
.
Figure 1: The status of products declared by Qilu Pharmaceutical
Figure 2: Gilead’s global sales of emtricitabine and propofol tenofovir (unit: million dollars)
Source: Mynet.
com's sales database of multinational listed companies
com's sales database of multinational listed companies
Gilead’s emtricitabine propofol tenofovir is suitable for use in combination with other antiretroviral drugs to treat human immunodeficiency virus type 1 ( HIV-1) infection
.
The compound preparation was approved by the FDA in 2016 and its global sales in 2020 will be close to 1.
9 billion U.
S.
dollars
.
.
The compound preparation was approved by the FDA in 2016 and its global sales in 2020 will be close to 1.
9 billion U.
S.
dollars
.
Figure 3: Sales of emtricitabine propofol tenofovir in the domestic market (unit: ten thousand yuan)
Source: Mi Nei Net Database
In 2018, NMPA approved Gilead’s fixed-dose compound formulation emtricitabine propofol tenofovir tablets (I: emtricitabine 200mg/ propofol tenofovir 10mg, II: emtricitabine 200mg/ propofol Tenofovir 25mg) is used for HIV treatment
.
According to data from Minai.
com, in 2020, the sales growth rate of emtricitabine and propofol tenofovir will be at the terminals of urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) in 2020.
487.
61%, and the growth rate of physical pharmacies in Chinese cities is also as high as 177.
78%.
The rapid increase of original research products in the domestic market has also attracted the attention of domestic pharmaceutical companies
.
.
According to data from Minai.
com, in 2020, the sales growth rate of emtricitabine and propofol tenofovir will be at the terminals of urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) in 2020.
487.
61%, and the growth rate of physical pharmacies in Chinese cities is also as high as 177.
78%.
The rapid increase of original research products in the domestic market has also attracted the attention of domestic pharmaceutical companies
.
Figure 4: Timeline of review of Tenofovir tablets with emtricitabine and propofol from Chengdu Better Pharmaceutical
Source: Meinenet MED2.
0 drug review database
0 drug review database
Chengdu Better Pharmaceuticals submitted an application for generic listing of four types of emtricitabine propofol tenofovir tablets (acceptance number CYHS1900772) in November 2019, and the acceptance number is currently under review and approval
.
From the perspective of the contracting time, Qilu Pharmaceutical is slightly inferior, but we will continue to follow up and report whether it can make a comeback in the end
.
.
From the perspective of the contracting time, Qilu Pharmaceutical is slightly inferior, but we will continue to follow up and report whether it can make a comeback in the end
.
Source: CDE official website, Minet database
The review data statistics are as of June 7.
If there are any errors or omissions, please correct me
.
If there are any errors or omissions, please correct me
.
Medical Network, June 8 News On June 7, Qilu Pharmaceutical declared the imitation listing of four types of emtricitabine propofol tenofovir tablets (I) and emtricitabine propofol tenofovir tablets (II).
Application, at present, only original research drugs in China have been approved for import in 2018, and no domestic generic drugs have been approved for the time being
.
Application, at present, only original research drugs in China have been approved for import in 2018, and no domestic generic drugs have been approved for the time being
.
Figure 1: The status of products declared by Qilu Pharmaceutical
Figure 2: Gilead’s global sales of emtricitabine and propofol tenofovir (unit: million dollars)
Source: Mynet.
com's sales database of multinational listed companies
com's sales database of multinational listed companies
Gilead’s emtricitabine propofol tenofovir is suitable for use in combination with other antiretroviral drugs to treat human immunodeficiency virus type 1 ( HIV-1) infection
.
The compound preparation was approved by the FDA in 2016 and its global sales in 2020 will be close to 1.
9 billion U.
S.
dollars
.
.
The compound preparation was approved by the FDA in 2016 and its global sales in 2020 will be close to 1.
9 billion U.
S.
dollars
.
Figure 3: Sales of emtricitabine propofol tenofovir in the domestic market (unit: ten thousand yuan)
Source: Mi Nei Net Database
In 2018, NMPA approved Gilead’s fixed-dose compound formulation emtricitabine propofol tenofovir tablets (I: emtricitabine 200mg/ propofol tenofovir 10mg, II: emtricitabine 200mg/ propofol Tenofovir 25mg) is used for HIV treatment
.
According to data from Minai.
com, in 2020, the sales growth rate of emtricitabine and propofol tenofovir will be at the terminals of urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) in 2020.
487.
61%, and the growth rate of physical pharmacies in Chinese cities is also as high as 177.
78%.
The rapid increase of original research products in the domestic market has also attracted the attention of domestic pharmaceutical companies
.
.
According to data from Minai.
com, in 2020, the sales growth rate of emtricitabine and propofol tenofovir will be at the terminals of urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) in 2020.
487.
61%, and the growth rate of physical pharmacies in Chinese cities is also as high as 177.
78%.
The rapid increase of original research products in the domestic market has also attracted the attention of domestic pharmaceutical companies
.
Figure 4: Timeline of review of Tenofovir tablets with emtricitabine and propofol from Chengdu Better Pharmaceutical
Source: Meinenet MED2.
0 drug review database
0 drug review database
Chengdu Better Pharmaceuticals submitted an application for generic listing of four types of emtricitabine propofol tenofovir tablets (acceptance number CYHS1900772) in November 2019, and the acceptance number is currently under review and approval
.
From the perspective of the contracting time, Qilu Pharmaceutical is slightly inferior, but we will continue to follow up and report whether it can make a comeback in the end
.
.
From the perspective of the contracting time, Qilu Pharmaceutical is slightly inferior, but we will continue to follow up and report whether it can make a comeback in the end
.
Source: CDE official website, Minet database
The review data statistics are as of June 7.
If there are any errors or omissions, please correct me
.
If there are any errors or omissions, please correct me
.
Medical Network, June 8 News On June 7, Qilu Pharmaceutical declared the imitation listing of four types of emtricitabine propofol tenofovir tablets (I) and emtricitabine propofol tenofovir tablets (II).
Application, at present, only original research drugs in China have been approved for import in 2018, and no domestic generic drugs have been approved for the time being
.
Application, at present, only original research drugs in China have been approved for import in 2018, and no domestic generic drugs have been approved for the time being
.
Figure 1: The status of products declared by Qilu Pharmaceutical
Figure 2: Gilead’s global sales of emtricitabine and propofol tenofovir (unit: million dollars)
Source: Mynet.
com's sales database of multinational listed companies
com's sales database of multinational listed companies
Gilead’s emtricitabine propofol tenofovir is suitable for use in combination with other antiretroviral drugs to treat human immunodeficiency virus type 1 ( HIV-1) infection
.
The compound preparation was approved by the FDA in 2016 and its global sales in 2020 will be close to 1.
9 billion U.
S.
dollars
.
.
The compound preparation was approved by the FDA in 2016 and its global sales in 2020 will be close to 1.
9 billion U.
S.
dollars
.
Figure 3: Sales of emtricitabine propofol tenofovir in the domestic market (unit: ten thousand yuan)
Source: Mi Nei Net Database
In 2018, NMPA approved Gilead’s fixed-dose compound formulation emtricitabine propofol tenofovir tablets (I: emtricitabine 200mg/ propofol tenofovir 10mg, II: emtricitabine 200mg/ propofol Tenofovir 25mg) is used for HIV treatment
.
According to data from Minai.
com, in 2020, the sales growth rate of emtricitabine and propofol tenofovir will be at the terminals of urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) in 2020.
487.
61%, and the growth rate of physical pharmacies in Chinese cities is also as high as 177.
78%.
The rapid increase of original research products in the domestic market has also attracted the attention of domestic pharmaceutical companies
.
Hospital hospital hospital pharmacy pharmacy pharmacy.
According to data from Minai.
com, in 2020, the sales growth rate of emtricitabine and propofol tenofovir will be at the terminals of urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) in 2020.
487.
61%, and the growth rate of physical pharmacies in Chinese cities is also as high as 177.
78%.
The rapid increase of original research products in the domestic market has also attracted the attention of domestic pharmaceutical companies
.
Figure 4: Timeline of review of Tenofovir tablets with emtricitabine and propofol from Chengdu Better Pharmaceutical
Source: Meinenet MED2.
0 drug review database
0 drug review database
Chengdu Better Pharmaceuticals submitted an application for generic listing of four types of emtricitabine propofol tenofovir tablets (acceptance number CYHS1900772) in November 2019, and the acceptance number is currently under review and approval
.
From the perspective of the contracting time, Qilu Pharmaceutical is slightly inferior, but we will continue to follow up and report whether it can make a comeback in the end
.
.
From the perspective of the contracting time, Qilu Pharmaceutical is slightly inferior, but we will continue to follow up and report whether it can make a comeback in the end
.
Source: CDE official website, Minet database
The review data statistics are as of June 7.
If there are any errors or omissions, please correct me
.
If there are any errors or omissions, please correct me
.
